« Return to News | Drug Sponsors | Ethics/Regulatory

Johnson & Johnson halts Doribax trial due to ‘significant safety concerns’

Monday, January 9, 2012 09:20 AM

Johnson & Johnson shut down a clinical trial of antibiotic Doribax after causing excess mortality and a numerically poorer cure rate than pneumonia subjects treated with imipenem-cilastatin, the generic version of Merck’s Primaxin.

Conducted as a post-marketing requirement of the European Medicines Agency, the trial was testing Doribax on 274 patients with ventilator-associated pneumonia. Results showed that those who received the drug had a 6.7% higher rate of death (21.5%) than patients treated with an alternative (14.8%). Patients also had an 11.2% lower rate of being cured than those receiving imipenem-cilastatin.

The FDA currently is reviewing the trial results, although Shaun Mickus, a spokesman at Janssen (the Johnson & Johnson unit that markets the drug), insisted that the drug is safe and effective when used according to the label.

Doribax is approved in Europe to treat hospital-acquired pneumonia, as well as in the U.S. to treat complicated urinary tract or abdominal infections.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.